Mximo Juda - Genomma Lab Advisor
Insider
Mximo Juda is Advisor of Genomma Lab Internacional
| Phone | 52 55 5081 0000 |
| Web | https://www.genommalab.com |
Genomma Lab Management Efficiency
The company has return on total asset (ROA) of 0.0921 % which means that it generated a profit of $0.0921 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1264 %, meaning that it generated $0.1264 on every $100 dollars invested by stockholders. Genomma Lab's management efficiency ratios could be used to measure how well Genomma Lab manages its routine affairs as well as how well it operates its assets and liabilities.Genomma Lab Internacional has accumulated 3.83 B in total debt with debt to equity ratio (D/E) of 0.51, which is about average as compared to similar companies. Genomma Lab Internacional has a current ratio of 1.64, which is within standard range for the sector. Debt can assist Genomma Lab until it has trouble settling it off, either with new capital or with free cash flow. So, Genomma Lab's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genomma Lab Internacional sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genomma to invest in growth at high rates of return. When we think about Genomma Lab's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Luiz Clavis | Hypera SA | N/A | |
| Lisa McCann | Alpha Teknova | 42 | |
| Adam Mostafa | Cumberland Pharmaceuticals | 45 | |
| Eric Shoemaker | C21 Investments | N/A | |
| Damon Terrill | Alpha Teknova | 53 | |
| Robert Weinstein | Petros Pharmaceuticals | 64 | |
| Dennis Urbaniak | Orexo AB | 54 | |
| Kurt Matheson | Organogenesis Holdings | N/A | |
| Cindy Patton | Cumberland Pharmaceuticals | 71 | |
| MD MBA | Orexo AB | N/A | |
| Sonny Newman | C21 Investments | N/A | |
| David Francisco | Organogenesis Holdings | 59 | |
| Hlio Segouras | Hypera SA | N/A | |
| Cecilia Coupland | Orexo AB | 47 | |
| Aaron Perlitsh | Lifecore Biomedical | N/A | |
| Zorina Pitkin | Organogenesis Holdings | N/A | |
| Fredrik Jarrsten | Orexo AB | 56 | |
| Robert Ronn | Orexo AB | 47 | |
| Joao Aguilar | Hypera SA | N/A | |
| Mauricio Christovam | Hypera SA | N/A | |
| BA Esq | Organogenesis Holdings | 55 | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 |
Genomma Lab Internacional Leadership Team
Elected by the shareholders, the Genomma Lab's board of directors comprises two types of representatives: Genomma Lab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genomma. The board's role is to monitor Genomma Lab's management team and ensure that shareholders' interests are well served. Genomma Lab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genomma Lab's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Efran Crdova, Deputy Sec | ||
| Engineer Galland, Exec CFO | ||
| Marianne Velasco, Global HR | ||
| Mximo Juda, Advisor | ||
| L Porres, Legal Officer | ||
| Daniel Neria, Head Relations | ||
| Jorge Valderrama, Chief Officer | ||
| Juan Sparvieri, Ex COO | ||
| Alejandro Patio, Media, Relations |
Genomma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Genomma Lab a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.09 B | |||
| Shares Outstanding | 1 B | |||
| Shares Owned By Insiders | 29.00 % | |||
| Shares Owned By Institutions | 29.10 % | |||
| Price To Earning | 11.09 X | |||
| Price To Book | 1.38 X |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Genomma Pink Sheet
If you are still planning to invest in Genomma Lab Internacional check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genomma Lab's history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |